COVID‑19 vaccination in liver transplant recipients (Review)

Severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) infection has significantly affected immunocompromised individuals and subsequently, liver transplant recipients (LTRs). Early in the course of pandemic, this vulnerable population was prioritized for vaccination, after obtaining encouragi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkoufa, Aikaterini, Saridaki, Maria, Georgakopoulou, Vasiliki Epameinondas, Spandidos, Demetrios A., Cholongitas, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189597/
https://www.ncbi.nlm.nih.gov/pubmed/37206557
http://dx.doi.org/10.3892/etm.2023.11990
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) infection has significantly affected immunocompromised individuals and subsequently, liver transplant recipients (LTRs). Early in the course of pandemic, this vulnerable population was prioritized for vaccination, after obtaining encouraging data about the vaccination benefits on disease severity and mortality. As the published knowledge was mainly supported from studies which were limited to the healthy population, the present review summarizes the data from the literature on coronavirus disease 2019 (COVID-19) vaccination in LTRs and the available vaccination guidelines of international societies. The COVID-19 vaccination of LTRs is strongly recommended as a safe and effective measure in order to prevent severe disease and mortality.

Ejemplares similares